To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Aida Pharmaceuticals Announces new Antibiotic Drug under Development
Aida Pharmaceuticals, Inc. has announced that its recently-acquired research institute in the Jiangsu Province, the Jiangsu Institute of Microbiology Co., Ltd (JSIM) is developing a new wide-spectrum antibiotic, Wetimicin, in the People's Republic of China.
Wetimicin is from the newest generation of amino-glycoside family of antibiotics and is being tested for the treatment of various inflammations, such as respiratory infection, urinogenital infection, soft skin tissue infection as well as infections from trauma and operations.
The research for this new drug started in 2000 and it is currently undergoing Phase 1 clinical trials in conjunction with the Chinese government's State Food and Drug Administration ("SFDA").
The company believes that Phase 2 testing will commence some time in 2008. The company will have the right of first refusal of the manufacturing and marketing of the drug once it is approved by the SFDA as a Category A innovative new drug.
